Alzai Health teams up with Centauri Health to market AI-driven Alzheimer’s risk identification in US

  • Alzai Health signed a U.S. commercialization teaming agreement with Centauri Health Solutions to market AI-driven Alzheimer’s risk stratification.
  • Centauri will use its provider and health plan relationships to support rollout across Medicare Advantage and other value-based care settings.
  • Alzai will provide its proprietary risk identification platform and technical expertise to accelerate a U.S. launch.
  • The partners are targeting earlier identification of high-risk patients for early-stage, undiagnosed Alzheimer’s disease.
  • The release cited more than 7 million U.S. patients, with direct care costs estimated at $384 billion annually.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzai Health Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607020649NEWSFILECNPR____20260702_303723_1) on July 02, 2026, and is solely responsible for the information contained therein.